ARTICLE | Regulation

Expanding the HAE tool kit

What patients told FDA they want from new HAE therapies

October 13, 2017 7:55 PM UTC

Despite an increasingly crowded market, hereditary angioedema patients who attended FDA’s Patient-Focused Drug Development meeting said there remains room for improvement in dosing convenience and reducing attack frequency.

Two subcutaneous prophylactics that have completed Phase III trials and two oral therapies in earlier clinical development have the potential to meet these patients’ needs...